指南与共识泌尿与男性生殖病理

ISUP共识:前列腺癌前驱病变工作组1报告建议

International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1: The Prostate.
指南 / 共识 · Am J Surg Pathol · 2025-06-23

国际泌尿病理学会(ISUP)癌症前驱病变会议工作组1于2024年9月评估了5种前列腺浸润癌前驱病变,包括HGPIN、IDC、AIP、AAH/腺瘤样变和PIA。通过投票(67%赞成定义为共识)形成推荐:低级别PIN无需报告;当邻近存在癌或可疑非典型小腺泡增生时,HGPIN无需报告;多灶性孤立HGPIN应继续报告;IDC诊断标准略作细化;筛状HGPIN重命名为AIP达成共识;AIP单独或伴1级癌需解释性注释;PIA或AAH/腺瘤样变作为相关阴性可选报告未达共识。

要点

  • 低级别PIN无需报告。
  • 当邻近存在癌或ASAP时,HGPIN无需报告。
  • 多灶性孤立HGPIN应继续报告。

核心结论

  • 共识反对报告低级别PIN。
  • 当邻近存在癌或可疑非典型小腺泡增生时,HGPIN无需报告。
  • 多灶性孤立HGPIN应继续报告。
  • IDC诊断标准略作细化:密集筛状或实性增生无需显著核异型即可诊断IDC。
  • 筛状HGPIN重命名为AIP达成共识;AIP单独或伴1级癌需解释性注释。

研究设计与样本

  • ISUP癌症前驱病变会议工作组1于2024年9月评估5种前列腺癌前驱病变。
  • 通过编译近期证据、调查当前实践并投票形成推荐,67%赞成定义为共识。

主要发现

  • 反对报告低级别PIN达成共识。
  • 当邻近存在癌或可疑非典型小腺泡增生时,HGPIN无需报告(活检或前列腺切除标本)。
  • 多灶性孤立HGPIN应继续报告达成共识;单灶HGPIN临床意义仍不确定。
  • 密集筛状或实性增生无需显著核异型即可诊断IDC达成共识;显著异型而无密集筛状/实性增生仅65%赞成,未达共识。
  • 筛状HGPIN重命名为AIP达成共识;AIP单独或伴1级癌需解释性注释达成共识;在浸润癌存在时报告AIP未达共识。

关键数值与推荐

  • 共识阈值:67%赞成。
  • 低级别PIN无需报告(共识)。
  • 邻近癌或ASAP时HGPIN无需报告(共识)。
  • 多灶性孤立HGPIN应报告(共识)。
  • AIP单独或伴GG1癌需解释性注释(共识);PIA或AAH/腺瘤样变作为相关阴性可选报告未达共识。

临床怎么用

  • 病理医生报告前列腺标本时,不应报告低级别PIN。
  • 当HGPIN邻近存在癌或ASAP时,无需报告HGPIN。
  • 多灶性孤立HGPIN应继续报告以提示后续癌风险。
  • 诊断IDC时,密集筛状或实性增生无需显著核异型。
  • 筛状HGPIN应命名为AIP;AIP单独或伴GG1癌时添加解释性注释。

局限性

  • 单灶HGPIN在活检中的临床意义仍不确定。
  • 显著异型而无密集筛状/实性增生诊断IDC未达共识(65%)。
  • 在浸润癌存在时报告AIP未达共识。
  • PIA或AAH/腺瘤样变作为相关阴性可选报告未达共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Working Group 1 at ISUP's Cancer Precursors meeting (September 2024) evaluated 5 putative precursors of invasive prostate cancer: high-grade prostatic intraepithelial neoplasia (HGPIN), intraductal carcinoma (IDC), atypical intraductal proliferation (AIP), atypical adenomatous hyperplasia (AAH)/adenosis, and proliferative inflammatory atrophy (PIA). Objectives were to compile recent evidence, interrogate current practices, and vote on recommendations, with 67% approval defined as consensus. Consensus was reached against the reporting of the low-grade form of PIN. HGPIN need not be reported when concomitant cancer or atypical small acinar proliferation suspicious for cancer exists adjacent to it, for biopsy or prostatectomy specimens. Finally, while the clinical significance of unifocal HGPIN in biopsies remains uncertain, there is stronger evidence for multifocal isolated HGPIN as a predictor of subsequent cancer detection. By consensus, multifocal HGPIN should continue being reported. Slight refinement was achieved regarding IDC criteria. The consensus opinion was that a dense cribriform to solid proliferation need not demonstrate marked nuclear atypia/ pleomorphism to qualify as IDC. The inverse scenario of marked atypia without dense cribriform/solid proliferation fell just short (65%) of consensus for IDC. Redesignating cribriform HGPIN as AIP achieved consensus. AIP found alone or with grade group 1 cancer warrants an explanatory comment. However, agreement was not attained to report AIP in the presence of invasive cancer, in either needle biopsy or prostatectomy. Finally, the optional reporting of PIA or AAH/adenosis in biopsies as pertinent negatives both fell short of consensus. This guidance should help pathologists standardize reporting, staying focused on the clinically actionable aspects of these lesions.

来源:Am J Surg Pathol,查看原文。版权归原作者所有。

引用

  1. Iczkowski KA, De Marzo AM, Agarwal N, et al. International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1: The Prostate. Am J Surg Pathol. 2025. PMID: 40545966. doi:10.1097/PAS.0000000000002430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。